Indication

Be indicated for treatment of CML with resistance or intolerance to prior therapy including Imatinib.

Highlights

T An inhibitor of wild BCR-ABL, much superior to Imatinib and nilotinib

Be listed as primary treatment in NCCN-2012 CML Treatment guideline

ADE is low, and the incidence rate of adverse event in the second year obviously decrease

Bioequivalent to the originator

Dosage form 

Tablet

Specification

20mg/tablet, 50mg/table

Originator]

Sprycel ® from Bristol Myers Squibb